Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of budesonide plus prednisolone for acute intestinal GVHD after allogeneic HSCT
jRCTs031200450Phase 2Completed
- Start
- Sep 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of budesonide in graft-versus-host disease (GVHD). Primary endpoint: Need for second-line therapy within 2 weeks. Started Sep 2022; status: completed.
02
Drugs
budesonide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on jRCTs031200450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200450.